A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

Inclusion Criteria:

• Patient meets DSM-IV-TR criteria for schizophrenia.
• Patient is aged 18 through 74 years at informed consent.
• Patient understands the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

• Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
• Patient has Parkinson's disease.
• Patient has a history or complication of malignancy.